<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03371355</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 703802-CS2</org_study_id>
    <nct_id>NCT03371355</nct_id>
  </id_info>
  <brief_title>Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akcea Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Akcea Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to&#xD;
      evaluate the safety, including tolerability, of ISIS 703802 and to assess the efficacy of&#xD;
      different doses and dosing regimens of ISIS 703802 on glucose and lipid metabolism, and liver&#xD;
      fat in participants with hypertriglyceridemia, Type 2 diabetes mellitus (T2DM), and&#xD;
      nonalcoholic fatty liver disease (NAFLD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Actual">February 24, 2020</completion_date>
  <primary_completion_date type="Actual">November 21, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Fasting Triglycerides Level at the Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the log ratio of Primary Analysis Time Point to Baseline. The estimate of the log ratio was converted back to the original scale and percent change was calculated using formula: = (ratio of Primary Analysis Time Point to Baseline - 1) × 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Angiopoietin-Like 3 Protein at the Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, and ApoAI at the Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Free Fatty Acid (FFA) at Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lipoprotein(a) (Lp[a]) at the Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in ANGPTL3, TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, ApoAI, FFA, and Lp(a) at Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the log ratio of Primary Analysis Time Point to Baseline. The estimate of the log ratio was converted back to the original scale and percent change was calculated using formula: = (ratio of Primary Analysis Time Point to Baseline - 1) × 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose at the Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin A1c (HbA1c) at the Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Insulin at the Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in and HOMA-IR at the Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>HOMA-IR is a method used to quantify insulin resistance. HOMA-IR is expressed as the following: HOMA-IR = fasting serum insulin (μU/mL) * fasting plasma glucose (mmol/L)/22.5. A negative change from Baseline indicates improvement. An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fructosamine at Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycated Albumin at the Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weight at the Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Weight, SBP and DBP at Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C6</time_frame>
    <description>An ANCOVA model was performed on the percent change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hepatic Fat Fraction (HFF) by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at the Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Hepatic Fat Fraction (HFF) by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at the Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the percent change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HFF ≤ 8% by MRI-PDFF at the Primary Analysis Time Point</measure>
    <time_frame>Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>The percentage of participants who achieved HFF ≤ 8% at the Primary Analysis Time Point was compared between each ISIS 703802 treatment group and pooled placebo group using a logistic regression model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fatty Liver Index (FLI) at the Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>The FLI was calculated by the following formula: FLI =(e0.953×loge[triglycerides]+0.139× Body Mass Index [BMI]+0.718×loge Gamma- Glutamyl Transferase [GGT]+0.053×waistcircumference-15.745)/ (1 + e0.953×loge[triglycerides]+0.139×BMI+0.718×loge [GGT]+0.053×waistcircumference-15.745) × 100. An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) at the Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Leptin at the Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Adiponectin at the Primary Analysis Time Point</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Subcutaneous Adipose Tissue (SAT) and Visceral Adipose Tissue (VAT) by Single Slice MRI at the Primary Analysis Timepoint</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist Circumference by Single Slice MRI at the Primary Analysis Timepoint</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist to Hip Ratio (WHR) at the Primary Analysis Timepoint</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Mass Index (BMI) at the Primary Analysis Timepoint</measure>
    <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
    <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to 13 weeks post treatment period (up to 39 weeks)</time_frame>
    <description>An AE was defined as any unfavorable and unintended sign (including a clinically-significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE was considered related to the investigational drug product. TEAEs were defined as adverse events that occurred after the first administration of study drug.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>NAFLD</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypertriglyceridemia</condition>
  <condition>Fatty Liver, Nonalcoholic</condition>
  <arm_group>
    <arm_group_label>Pooled Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants from each cohort received placebo at a dose-matched volume of study drug, subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: ISIS 703802, 40 mg Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received ISIS 703802, 40 milligrams (mg) SC once every 4 weeks for 6 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: ISIS 703802, 80 mg Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A: ISIS 703802, 20 mg QW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received ISIS 703802, 20 mg once every week for 26 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (Matched with ISIS 703802)</description>
    <arm_group_label>Pooled Placebo</arm_group_label>
    <other_name>Sterile Normal Saline (0.9% NaCl)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 703802 40 mg</intervention_name>
    <description>ISIS 703802 40 mg, administered via SC injection, once every 4 weeks for 6 doses.</description>
    <arm_group_label>Cohort B: ISIS 703802, 40 mg Q4W</arm_group_label>
    <other_name>AKCEA-ANGPTL3-LRx</other_name>
    <other_name>IONIS-ANGPTL3-LRx</other_name>
    <other_name>Vupanorsen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 703802 80 mg</intervention_name>
    <description>ISIS 703802 80 mg, administered via SC injection, once every 4 weeks for 6 doses.</description>
    <arm_group_label>Cohort C: ISIS 703802, 80 mg Q4W</arm_group_label>
    <other_name>AKCEA-ANGPTL3-LRx</other_name>
    <other_name>IONIS-ANGPTL3-LRx</other_name>
    <other_name>Vupanorsen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 703802 20 mg</intervention_name>
    <description>ISIS 703802 20 mg, administered via SC injection, once every week for 26 doses.</description>
    <arm_group_label>Cohort A: ISIS 703802, 20 mg QW</arm_group_label>
    <other_name>AKCEA-ANGPTL3-LRx</other_name>
    <other_name>IONIS-ANGPTL3-LRx</other_name>
    <other_name>Vupanorsen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Plasma triglycerides (TG) at Screening greater than (&gt;)150 milligrams per deciliter&#xD;
             (mg/dL) and at qualification of &gt;150 mg/dL.&#xD;
&#xD;
          -  Documented history of hepatic steatosis with baseline magnetic resonance imaging (MRI)&#xD;
             indicating hepatic fat fraction (HFF) greater than (&gt;) 8%.&#xD;
&#xD;
          -  Diagnosis of Type 2 diabetes mellitus with hemoglobin A1c (HbA1c) &gt;6.5 and less than&#xD;
             or equal to (≤) 10% at Screening.&#xD;
&#xD;
          -  Must have been on a stable dose of oral antidiabetic therapy for a minimum of 3 months&#xD;
             prior to Screening.&#xD;
&#xD;
          -  Body mass index between 27- 40 kilograms per meter square (kg/m^2), inclusive, at&#xD;
             Screening.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus.&#xD;
&#xD;
          -  Active chronic liver disease, alcoholic liver disease, Wilson's disease&#xD;
             hemochromatosis, primary biliary cirrhosis, primary sclerosing cholangitis, genetic&#xD;
             hemochromatosis, known or suspected hepatocellular carcinoma, history of or planned&#xD;
             liver transplant for end-stage liver disease of any etiology.&#xD;
&#xD;
          -  Documented history of advanced liver fibrosis.&#xD;
&#xD;
          -  History of cirrhosis and/or hepatic decompensation including ascites, hepatic&#xD;
             encephalopathy, or variceal bleeding.&#xD;
&#xD;
          -  History of clinically significant acute cardiac event within 6 months before&#xD;
             Screening.&#xD;
&#xD;
          -  History of heart failure with New York Heart Association (NYHA) greater than Class II.&#xD;
&#xD;
          -  Use of Insulin or insulin analogs, glucagon-like peptide-1 (GLP-1) agonists, and&#xD;
             peroxisome proliferator-activated receptor gamma (PPARᵞ) agonists (pioglitazone or&#xD;
             rosiglitazone).&#xD;
&#xD;
          -  Weight change &gt;5% within 3 months before Screening.&#xD;
&#xD;
          -  Conditions contraindicated for magnetic resonance imaging (MRI) procedures including&#xD;
             any metal implant (example, heart pacemaker, rods, screws, aneurysm clips).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Sites</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Fountain Hills</city>
        <state>Arizona</state>
        <zip>85268</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Jensen Beach</city>
        <state>Florida</state>
        <zip>34957</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Bridgeton</city>
        <state>New Jersey</state>
        <zip>08302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78735</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3M 3E5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 7K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 2C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <results_first_submitted>December 22, 2020</results_first_submitted>
  <results_first_submitted_qc>January 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 1, 2021</results_first_posted>
  <disposition_first_submitted>November 19, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>January 28, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 1, 2021</disposition_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Hepatic Steatosis</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>AKCEA-ANGPTL3-Lrx</keyword>
  <keyword>IONIS-ANGPTL3-Lrx</keyword>
  <keyword>Fatty Liver</keyword>
  <keyword>Fatty Liver Without Mention of Alcohol</keyword>
  <keyword>Liver Fat</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Diabetes Mellitus Type 2 in Nonobese</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Triglycerides High</keyword>
  <keyword>High Triglycerides</keyword>
  <keyword>Metabolic Disease</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Digestive System Disease</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Vupanorsen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 21, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03371355/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03371355/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 42 study centers; 38 sites in the US and 4 sites in Canada.</recruitment_details>
      <pre_assignment_details>A total of 525 participants were screened. 105 were randomized in a 1:1:1 ratio to Cohorts A, B, or C. In each cohort, participants were randomized in a 3:1 ratio to receive ISIS 703802 or matching volume of placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pooled Placebo</title>
          <description>Participants from each cohort received placebo at a dose-matched volume of study drug, subcutaneously (SC).</description>
        </group>
        <group group_id="P2">
          <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
          <description>Participants received ISIS 703802, 40 milligrams (mg) SC once every 4 weeks for 6 doses.</description>
        </group>
        <group group_id="P3">
          <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
          <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
        </group>
        <group group_id="P4">
          <title>Cohort A: ISIS 703802, 20 mg QW</title>
          <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Investigator judgment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS) population included all participants who were randomized and received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Pooled Placebo</title>
          <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
        </group>
        <group group_id="B2">
          <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
          <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
        </group>
        <group group_id="B3">
          <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
          <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
        </group>
        <group group_id="B4">
          <title>Cohort A: ISIS 703802, 20 mg QW</title>
          <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.1" spread="7.29"/>
                    <measurement group_id="B2" value="52.0" spread="10.34"/>
                    <measurement group_id="B3" value="54.8" spread="6.04"/>
                    <measurement group_id="B4" value="56.0" spread="8.45"/>
                    <measurement group_id="B5" value="53.5" spread="8.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Triglycerides (TG)</title>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="275.5" spread="110.38"/>
                    <measurement group_id="B2" value="414.9" spread="456.86"/>
                    <measurement group_id="B3" value="292.2" spread="130.98"/>
                    <measurement group_id="B4" value="311.8" spread="155.92"/>
                    <measurement group_id="B5" value="323.1" spread="257.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angiopoietin Like 3 (ANGPTL3)</title>
          <units>micrograms per liter (μg/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114.85" spread="32.066"/>
                    <measurement group_id="B2" value="102.36" spread="28.923"/>
                    <measurement group_id="B3" value="111.86" spread="37.463"/>
                    <measurement group_id="B4" value="108.60" spread="42.722"/>
                    <measurement group_id="B5" value="109.47" spread="35.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol (TC)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202.1" spread="43.64"/>
                    <measurement group_id="B2" value="200.7" spread="45.27"/>
                    <measurement group_id="B3" value="191.2" spread="61.63"/>
                    <measurement group_id="B4" value="182.4" spread="47.06"/>
                    <measurement group_id="B5" value="194.2" spread="49.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non- High density lipoprotein cholesterol (Non-HDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162.7" spread="39.90"/>
                    <measurement group_id="B2" value="164.3" spread="47.50"/>
                    <measurement group_id="B3" value="154.1" spread="58.28"/>
                    <measurement group_id="B4" value="146.8" spread="46.79"/>
                    <measurement group_id="B5" value="157.0" spread="48.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High density lipoprotein cholesterol (HDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.4" spread="10.43"/>
                    <measurement group_id="B2" value="36.3" spread="10.54"/>
                    <measurement group_id="B3" value="37.1" spread="10.37"/>
                    <measurement group_id="B4" value="35.6" spread="9.89"/>
                    <measurement group_id="B5" value="37.1" spread="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low Density Lipoprotein Cholesterol (LDL-C)</title>
          <description>LDL-C was calculated by using the precipitation method.</description>
          <population>Number analyzed signifies the number of participants with data available for LDL-C.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="25"/>
                    <count group_id="B5" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111.5" spread="43.06"/>
                    <measurement group_id="B2" value="98.2" spread="36.13"/>
                    <measurement group_id="B3" value="101.0" spread="53.13"/>
                    <measurement group_id="B4" value="88.6" spread="37.69"/>
                    <measurement group_id="B5" value="99.8" spread="43.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Very Low Density Lipoprotein Cholesterol (VLDL-C)</title>
          <population>Number analyzed signifies the number of participants with data available for VLDL-C.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="25"/>
                    <count group_id="B5" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" spread="12.90"/>
                    <measurement group_id="B2" value="52.6" spread="14.59"/>
                    <measurement group_id="B3" value="47.6" spread="9.92"/>
                    <measurement group_id="B4" value="49.6" spread="13.11"/>
                    <measurement group_id="B5" value="49.4" spread="12.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein CIII (ApoCIII)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.48" spread="3.981"/>
                    <measurement group_id="B2" value="18.71" spread="11.024"/>
                    <measurement group_id="B3" value="15.54" spread="4.969"/>
                    <measurement group_id="B4" value="16.19" spread="5.562"/>
                    <measurement group_id="B5" value="16.21" spread="7.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein A1 (ApoA1)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141.3" spread="19.30"/>
                    <measurement group_id="B2" value="137.9" spread="21.12"/>
                    <measurement group_id="B3" value="139.1" spread="24.12"/>
                    <measurement group_id="B4" value="133.3" spread="20.18"/>
                    <measurement group_id="B5" value="137.9" spread="21.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B (ApoB)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108.68" spread="25.254"/>
                    <measurement group_id="B2" value="105.90" spread="25.868"/>
                    <measurement group_id="B3" value="105.34" spread="36.160"/>
                    <measurement group_id="B4" value="95.48" spread="26.210"/>
                    <measurement group_id="B5" value="103.90" spread="28.721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B48 (ApoB-48)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.63" spread="1.455"/>
                    <measurement group_id="B2" value="3.21" spread="2.239"/>
                    <measurement group_id="B3" value="3.20" spread="2.863"/>
                    <measurement group_id="B4" value="3.48" spread="3.228"/>
                    <measurement group_id="B5" value="3.13" spread="2.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B100 (ApoB-100)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105.89" spread="25.699"/>
                    <measurement group_id="B2" value="102.48" spread="25.740"/>
                    <measurement group_id="B3" value="102.14" spread="35.392"/>
                    <measurement group_id="B4" value="91.79" spread="25.871"/>
                    <measurement group_id="B5" value="100.62" spread="28.540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lipoprotein-a (Lp[a])</title>
          <units>nanomoles per liter (nmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.7" spread="66.79"/>
                    <measurement group_id="B2" value="58.2" spread="74.74"/>
                    <measurement group_id="B3" value="46.7" spread="74.88"/>
                    <measurement group_id="B4" value="38.3" spread="54.81"/>
                    <measurement group_id="B5" value="48.8" spread="67.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Free Fatty Acid (FFA)</title>
          <units>millimole per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.62" spread="0.261"/>
                    <measurement group_id="B2" value="0.66" spread="0.266"/>
                    <measurement group_id="B3" value="0.61" spread="0.237"/>
                    <measurement group_id="B4" value="0.58" spread="0.213"/>
                    <measurement group_id="B5" value="0.62" spread="0.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin</title>
          <population>Number analyzed signifies the number of participants with data available for insulin.</population>
          <units>milli international units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="25"/>
                    <count group_id="B4" value="25"/>
                    <count group_id="B5" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.35" spread="16.965"/>
                    <measurement group_id="B2" value="21.35" spread="12.602"/>
                    <measurement group_id="B3" value="26.32" spread="15.353"/>
                    <measurement group_id="B4" value="23.19" spread="12.887"/>
                    <measurement group_id="B5" value="24.31" spread="14.542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma Glucose</title>
          <population>Number analyzed signifies the number of participants with data available for plasma glucose.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="25"/>
                    <count group_id="B4" value="25"/>
                    <count group_id="B5" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="188.6" spread="59.06"/>
                    <measurement group_id="B2" value="182.6" spread="58.87"/>
                    <measurement group_id="B3" value="201.4" spread="52.16"/>
                    <measurement group_id="B4" value="164.6" spread="47.69"/>
                    <measurement group_id="B5" value="184.4" spread="55.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</title>
          <description>HOMA-IR is a method used to quantify insulin resistance. HOMA-IR is expressed as the following: HOMA-IR = fasting serum insulin (microunits per milliliter [μU/Ml]) * fasting plasma glucose (millimoles/liter [mmol/L])/22.5.</description>
          <population>Number analyzed signifies the number of participants with data available for HOMA-IR.</population>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="25"/>
                    <count group_id="B4" value="25"/>
                    <count group_id="B5" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.40" spread="8.548"/>
                    <measurement group_id="B2" value="9.42" spread="6.178"/>
                    <measurement group_id="B3" value="13.02" spread="8.331"/>
                    <measurement group_id="B4" value="9.54" spread="6.278"/>
                    <measurement group_id="B5" value="11.10" spread="7.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fructosamine</title>
          <units>micromoles per liter (μmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="325.2" spread="49.62"/>
                    <measurement group_id="B2" value="302.7" spread="65.51"/>
                    <measurement group_id="B3" value="317.6" spread="59.33"/>
                    <measurement group_id="B4" value="312.9" spread="48.19"/>
                    <measurement group_id="B5" value="314.7" spread="55.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycated Albumin</title>
          <units>grams per deciliter (g/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.84" spread="0.183"/>
                    <measurement group_id="B2" value="0.74" spread="0.254"/>
                    <measurement group_id="B3" value="0.80" spread="0.216"/>
                    <measurement group_id="B4" value="0.79" spread="0.187"/>
                    <measurement group_id="B5" value="0.79" spread="0.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1C (HbA1C)</title>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.30" spread="1.260"/>
                    <measurement group_id="B2" value="8.04" spread="1.113"/>
                    <measurement group_id="B3" value="8.36" spread="1.091"/>
                    <measurement group_id="B4" value="8.19" spread="0.901"/>
                    <measurement group_id="B5" value="8.22" spread="1.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatic Fat Fraction (HFF)</title>
          <units>percentage (Hepatic Fat Fraction)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.84" spread="6.144"/>
                    <measurement group_id="B2" value="17.17" spread="6.150"/>
                    <measurement group_id="B3" value="17.23" spread="7.262"/>
                    <measurement group_id="B4" value="19.32" spread="10.445"/>
                    <measurement group_id="B5" value="17.63" spread="7.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Subcutaneous Adipose Tissue (SAT)</title>
          <units>millimeters square (mm^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2634.49" spread="1235.433"/>
                    <measurement group_id="B2" value="3076.36" spread="1114.681"/>
                    <measurement group_id="B3" value="3021.37" spread="1080.432"/>
                    <measurement group_id="B4" value="2701.94" spread="1000.756"/>
                    <measurement group_id="B5" value="2856.41" spread="1113.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visceral Adipose Tissue (VAT),</title>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2275.05" spread="605.492"/>
                    <measurement group_id="B2" value="2690.34" spread="888.431"/>
                    <measurement group_id="B3" value="2826.84" spread="1105.086"/>
                    <measurement group_id="B4" value="2773.11" spread="894.630"/>
                    <measurement group_id="B5" value="2637.85" spread="903.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fatty Liver Index (FLI)</title>
          <description>The FLI was calculated by the following formula: FLI =(e0.953×loge[triglycerides]+0.139× Body Mass Index[BMI]+0.718×loge Gamma- Glutamyl Transferase [GGT]+0.053×waistcircumference-15.745)/ (1 +e0.953×loge[triglycerides]+0.139×BMI+0.718×loge [GGT]+0.053×waistcircumference-15.745) × 100.</description>
          <population>Number analyzed signifies the number of participants with data available for FLI.</population>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.20" spread="22.618"/>
                    <measurement group_id="B2" value="85.55" spread="12.802"/>
                    <measurement group_id="B3" value="83.16" spread="19.846"/>
                    <measurement group_id="B4" value="84.45" spread="13.926"/>
                    <measurement group_id="B5" value="82.51" spread="17.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.3" spread="10.64"/>
                    <measurement group_id="B2" value="92.5" spread="16.66"/>
                    <measurement group_id="B3" value="90.7" spread="20.83"/>
                    <measurement group_id="B4" value="92.0" spread="16.39"/>
                    <measurement group_id="B5" value="88.5" spread="17.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kilograms per meter square (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.3" spread="3.03"/>
                    <measurement group_id="B2" value="32.8" spread="3.97"/>
                    <measurement group_id="B3" value="32.1" spread="3.84"/>
                    <measurement group_id="B4" value="32.3" spread="4.19"/>
                    <measurement group_id="B5" value="31.9" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist to Hip Ratio</title>
          <population>Number analyzed signifies the number of participants with data available for waist to hip ratio.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="25"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.98" spread="0.070"/>
                    <measurement group_id="B2" value="1.05" spread="0.225"/>
                    <measurement group_id="B3" value="1.01" spread="0.216"/>
                    <measurement group_id="B4" value="0.97" spread="0.068"/>
                    <measurement group_id="B5" value="1.00" spread="0.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Fasting Triglycerides Level at the Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the log ratio of Primary Analysis Time Point to Baseline. The estimate of the log ratio was converted back to the original scale and percent change was calculated using formula: = (ratio of Primary Analysis Time Point to Baseline - 1) × 100.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Triglycerides Level at the Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the log ratio of Primary Analysis Time Point to Baseline. The estimate of the log ratio was converted back to the original scale and percent change was calculated using formula: = (ratio of Primary Analysis Time Point to Baseline - 1) × 100.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug.</population>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16" lower_limit="-29" upper_limit="0"/>
                    <measurement group_id="O2" value="-36" lower_limit="-47" upper_limit="-23"/>
                    <measurement group_id="O3" value="-53" lower_limit="-60" upper_limit="-43"/>
                    <measurement group_id="O4" value="-47" lower_limit="-57" upper_limit="-35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0343</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41</ci_lower_limit>
            <ci_upper_limit>-2</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56</ci_lower_limit>
            <ci_upper_limit>-28</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52</ci_lower_limit>
            <ci_upper_limit>-17</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Angiopoietin-Like 3 Protein at the Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Angiopoietin-Like 3 Protein at the Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>μg/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.77" lower_limit="-2.09" upper_limit="15.62"/>
                    <measurement group_id="O2" value="-43.11" lower_limit="-52.27" upper_limit="-33.94"/>
                    <measurement group_id="O3" value="-64.89" lower_limit="-74.26" upper_limit="-55.53"/>
                    <measurement group_id="O4" value="-52.98" lower_limit="-63.99" upper_limit="-41.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-49.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.68</ci_lower_limit>
            <ci_upper_limit>-37.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-71.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-84.47</ci_lower_limit>
            <ci_upper_limit>-58.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-59.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-74.04</ci_lower_limit>
            <ci_upper_limit>-45.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, and ApoAI at the Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, 'number analyzed' (n) signifies participants evaluable for this outcome measure for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, and ApoAI at the Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, 'number analyzed' (n) signifies participants evaluable for this outcome measure for each specified category.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" lower_limit="-15.19" upper_limit="5.51"/>
                    <measurement group_id="O2" value="-21.3" lower_limit="-32.35" upper_limit="-10.31"/>
                    <measurement group_id="O3" value="-41.9" lower_limit="-52.88" upper_limit="-30.89"/>
                    <measurement group_id="O4" value="-36.5" lower_limit="-49.38" upper_limit="-23.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" lower_limit="-11.21" upper_limit="6.14"/>
                    <measurement group_id="O2" value="5.0" lower_limit="-4.78" upper_limit="14.70"/>
                    <measurement group_id="O3" value="-11.1" lower_limit="-20.38" upper_limit="-1.90"/>
                    <measurement group_id="O4" value="-11.3" lower_limit="-21.76" upper_limit="-0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="-0.38" upper_limit="4.69"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-3.25" upper_limit="2.14"/>
                    <measurement group_id="O3" value="-6.4" lower_limit="-9.13" upper_limit="-3.77"/>
                    <measurement group_id="O4" value="-2.0" lower_limit="-5.11" upper_limit="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" lower_limit="-11.64" upper_limit="-1.34"/>
                    <measurement group_id="O2" value="-15.6" lower_limit="-21.47" upper_limit="-9.78"/>
                    <measurement group_id="O3" value="-21.9" lower_limit="-27.41" upper_limit="-16.36"/>
                    <measurement group_id="O4" value="-17.3" lower_limit="-23.48" upper_limit="-11.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" lower_limit="-17.45" upper_limit="3.44"/>
                    <measurement group_id="O2" value="-20.9" lower_limit="-32.01" upper_limit="-9.70"/>
                    <measurement group_id="O3" value="-35.4" lower_limit="-46.54" upper_limit="-24.33"/>
                    <measurement group_id="O4" value="-34.4" lower_limit="-47.39" upper_limit="-21.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.63" lower_limit="-9.98" upper_limit="2.71"/>
                    <measurement group_id="O2" value="-6.08" lower_limit="-12.82" upper_limit="0.66"/>
                    <measurement group_id="O3" value="-13.46" lower_limit="-20.20" upper_limit="-6.72"/>
                    <measurement group_id="O4" value="-8.91" lower_limit="-16.91" upper_limit="-0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB: ApoB-48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.139" lower_limit="-0.90" upper_limit="0.62"/>
                    <measurement group_id="O2" value="-1.140" lower_limit="-1.93" upper_limit="-0.35"/>
                    <measurement group_id="O3" value="-1.942" lower_limit="-2.75" upper_limit="-1.14"/>
                    <measurement group_id="O4" value="-1.230" lower_limit="-2.16" upper_limit="-0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB: ApoB-100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.757" lower_limit="-9.94" upper_limit="2.43"/>
                    <measurement group_id="O2" value="-4.643" lower_limit="-11.21" upper_limit="1.92"/>
                    <measurement group_id="O3" value="-11.346" lower_limit="-17.91" upper_limit="-4.78"/>
                    <measurement group_id="O4" value="-7.174" lower_limit="-14.97" upper_limit="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoCIII</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.729" lower_limit="-2.58" upper_limit="1.12"/>
                    <measurement group_id="O2" value="-5.482" lower_limit="-7.42" upper_limit="-3.54"/>
                    <measurement group_id="O3" value="-9.228" lower_limit="-11.18" upper_limit="-7.28"/>
                    <measurement group_id="O4" value="-7.588" lower_limit="-9.86" upper_limit="-5.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoA1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="-1.11" upper_limit="11.15"/>
                    <measurement group_id="O2" value="-11.8" lower_limit="-18.32" upper_limit="-5.30"/>
                    <measurement group_id="O3" value="-30.1" lower_limit="-36.63" upper_limit="-23.65"/>
                    <measurement group_id="O4" value="-16.1" lower_limit="-23.68" upper_limit="-8.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TC</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0327</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-16.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.59</ci_lower_limit>
            <ci_upper_limit>-1.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TC</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-37.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.15</ci_lower_limit>
            <ci_upper_limit>-21.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>TC</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-31.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.23</ci_lower_limit>
            <ci_upper_limit>-15.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2560</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>7.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.55</ci_lower_limit>
            <ci_upper_limit>20.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>LDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1795</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-8.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.26</ci_lower_limit>
            <ci_upper_limit>4.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>LDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2065</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-8.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.48</ci_lower_limit>
            <ci_upper_limit>4.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1515</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.43</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>HDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-8.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.29</ci_lower_limit>
            <ci_upper_limit>-4.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>HDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0436</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.18</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>VLDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0224</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-9.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.94</ci_lower_limit>
            <ci_upper_limit>-1.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>VLDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-15.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.94</ci_lower_limit>
            <ci_upper_limit>-7.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>VLDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0091</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-10.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.86</ci_lower_limit>
            <ci_upper_limit>-2.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-HDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0748</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-13.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.12</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non-HDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-28.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.68</ci_lower_limit>
            <ci_upper_limit>-13.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-HDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0016</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-27.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.08</ci_lower_limit>
            <ci_upper_limit>-10.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ApoB</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6005</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.68</ci_lower_limit>
            <ci_upper_limit>6.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ApoB</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0374</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-9.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.07</ci_lower_limit>
            <ci_upper_limit>-0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ApoB</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3100</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-5.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.55</ci_lower_limit>
            <ci_upper_limit>5.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ApoB-48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0728</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.002</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.10</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ApoB-48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0018</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.803</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.91</ci_lower_limit>
            <ci_upper_limit>-0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ApoB-48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0759</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.091</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.30</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ApoB-100</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8451</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.887</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.89</ci_lower_limit>
            <ci_upper_limit>8.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ApoB-100</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0973</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-7.590</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.59</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ApoB-100</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5000</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-3.418</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.45</ci_lower_limit>
            <ci_upper_limit>6.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ApoCIII</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-4.753</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.47</ci_lower_limit>
            <ci_upper_limit>-2.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ApoCIII</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-8.499</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.18</ci_lower_limit>
            <ci_upper_limit>-5.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ApoCIII</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-6.860</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.78</ci_lower_limit>
            <ci_upper_limit>-3.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ApoA1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-16.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.80</ci_lower_limit>
            <ci_upper_limit>-7.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ApoA1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-35.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.07</ci_lower_limit>
            <ci_upper_limit>-26.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ApoA1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-21.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.89</ci_lower_limit>
            <ci_upper_limit>-11.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Free Fatty Acid (FFA) at Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Free Fatty Acid (FFA) at Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0734" lower_limit="-0.15" upper_limit="0.01"/>
                    <measurement group_id="O2" value="-0.0607" lower_limit="-0.15" upper_limit="0.02"/>
                    <measurement group_id="O3" value="-0.0878" lower_limit="-0.17" upper_limit="0.00"/>
                    <measurement group_id="O4" value="-0.0881" lower_limit="-0.19" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8299</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.0128</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8102</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.0144</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8223</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.0146</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lipoprotein(a) (Lp[a]) at the Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lipoprotein(a) (Lp[a]) at the Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>nmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-6.67" upper_limit="4.51"/>
                    <measurement group_id="O2" value="6.8" lower_limit="0.76" upper_limit="12.75"/>
                    <measurement group_id="O3" value="0.5" lower_limit="-5.47" upper_limit="6.44"/>
                    <measurement group_id="O4" value="-2.8" lower_limit="-9.74" upper_limit="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lp(a)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0604</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>7.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>16.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Lp(a)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7048</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.61</ci_lower_limit>
            <ci_upper_limit>9.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Lp(a)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7024</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.65</ci_lower_limit>
            <ci_upper_limit>7.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in ANGPTL3, TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, ApoAI, FFA, and Lp(a) at Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the log ratio of Primary Analysis Time Point to Baseline. The estimate of the log ratio was converted back to the original scale and percent change was calculated using formula: = (ratio of Primary Analysis Time Point to Baseline - 1) × 100.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, 'n' signifies participants evaluable for this outcome measure for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in ANGPTL3, TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, ApoAI, FFA, and Lp(a) at Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the log ratio of Primary Analysis Time Point to Baseline. The estimate of the log ratio was converted back to the original scale and percent change was calculated using formula: = (ratio of Primary Analysis Time Point to Baseline - 1) × 100.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, 'n' signifies participants evaluable for this outcome measure for each specified category.</population>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANGPTL3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="-6" upper_limit="23"/>
                    <measurement group_id="O2" value="-41" lower_limit="-48" upper_limit="-32"/>
                    <measurement group_id="O3" value="-59" lower_limit="-64" upper_limit="-53"/>
                    <measurement group_id="O4" value="-54" lower_limit="-61" upper_limit="-46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-8" upper_limit="4"/>
                    <measurement group_id="O2" value="-11" lower_limit="-16" upper_limit="-5"/>
                    <measurement group_id="O3" value="-21" lower_limit="-26" upper_limit="-16"/>
                    <measurement group_id="O4" value="-19" lower_limit="-25" upper_limit="-13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-8" upper_limit="9"/>
                    <measurement group_id="O2" value="6" lower_limit="-4" upper_limit="17"/>
                    <measurement group_id="O3" value="-7" lower_limit="-15" upper_limit="2"/>
                    <measurement group_id="O4" value="-12" lower_limit="-21" upper_limit="-3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="-2" upper_limit="16"/>
                    <measurement group_id="O2" value="-2" lower_limit="-10" upper_limit="8"/>
                    <measurement group_id="O3" value="-18" lower_limit="-25" upper_limit="-11"/>
                    <measurement group_id="O4" value="-4" lower_limit="-13" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14" lower_limit="-26" upper_limit="0"/>
                    <measurement group_id="O2" value="-35" lower_limit="-45" upper_limit="-23"/>
                    <measurement group_id="O3" value="-47" lower_limit="-55" upper_limit="-37"/>
                    <measurement group_id="O4" value="-40" lower_limit="-50" upper_limit="-28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" lower_limit="-11" upper_limit="3"/>
                    <measurement group_id="O2" value="-13" lower_limit="-20" upper_limit="-7"/>
                    <measurement group_id="O3" value="-21" lower_limit="-27" upper_limit="-15"/>
                    <measurement group_id="O4" value="-22" lower_limit="-29" upper_limit="-15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" lower_limit="-9" upper_limit="3"/>
                    <measurement group_id="O2" value="-7" lower_limit="-12" upper_limit="0"/>
                    <measurement group_id="O3" value="-12" lower_limit="-17" upper_limit="-6"/>
                    <measurement group_id="O4" value="-10" lower_limit="-17" upper_limit="-3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB: ApoB-48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21" lower_limit="-40" upper_limit="5"/>
                    <measurement group_id="O2" value="-44" lower_limit="-58" upper_limit="-25"/>
                    <measurement group_id="O3" value="-62" lower_limit="-72" upper_limit="-49"/>
                    <measurement group_id="O4" value="-38" lower_limit="-56" upper_limit="-12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB: ApoB-100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" lower_limit="-9" upper_limit="3"/>
                    <measurement group_id="O2" value="-5" lower_limit="-11" upper_limit="1"/>
                    <measurement group_id="O3" value="-10" lower_limit="-16" upper_limit="-4"/>
                    <measurement group_id="O4" value="-9" lower_limit="-15" upper_limit="-1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoCIII</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6" lower_limit="-22" upper_limit="14"/>
                    <measurement group_id="O2" value="-40" lower_limit="-51" upper_limit="-27"/>
                    <measurement group_id="O3" value="-61" lower_limit="-68" upper_limit="-52"/>
                    <measurement group_id="O4" value="-50" lower_limit="-61" upper_limit="-37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoA1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="-4" upper_limit="11"/>
                    <measurement group_id="O2" value="-9" lower_limit="-15" upper_limit="-2"/>
                    <measurement group_id="O3" value="-24" lower_limit="-29" upper_limit="-18"/>
                    <measurement group_id="O4" value="-12" lower_limit="-19" upper_limit="-4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FFA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" lower_limit="-24" upper_limit="4"/>
                    <measurement group_id="O2" value="-12" lower_limit="-25" upper_limit="3"/>
                    <measurement group_id="O3" value="-18" lower_limit="-31" upper_limit="-4"/>
                    <measurement group_id="O4" value="-11" lower_limit="-27" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lp(a)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="-8" upper_limit="15"/>
                    <measurement group_id="O2" value="-4" lower_limit="-15" upper_limit="8"/>
                    <measurement group_id="O3" value="-3" lower_limit="-14" upper_limit="9"/>
                    <measurement group_id="O4" value="-1" lower_limit="-14" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANGPTL3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54</ci_lower_limit>
            <ci_upper_limit>-33</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANGPTL3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-69</ci_lower_limit>
            <ci_upper_limit>-54</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANGPTL3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-66</ci_lower_limit>
            <ci_upper_limit>-47</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TC</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0309</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16</ci_lower_limit>
            <ci_upper_limit>-1</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TC</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26</ci_lower_limit>
            <ci_upper_limit>-12</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>TC</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25</ci_lower_limit>
            <ci_upper_limit>-9</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4016</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7</ci_lower_limit>
            <ci_upper_limit>21</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>LDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2589</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18</ci_lower_limit>
            <ci_upper_limit>6</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>LDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0616</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1918</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>HDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32</ci_lower_limit>
            <ci_upper_limit>-14</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>HDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1132</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>VLDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0177</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40</ci_lower_limit>
            <ci_upper_limit>-5</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>VLDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51</ci_lower_limit>
            <ci_upper_limit>-23</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>VLDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0033</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45</ci_lower_limit>
            <ci_upper_limit>-12</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-HDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0523</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non-HDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26</ci_lower_limit>
            <ci_upper_limit>-9</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-HDL-C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28</ci_lower_limit>
            <ci_upper_limit>-9</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ApoB</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4204</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ApoB</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0441</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ApoB</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1324</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ApoB-48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1009</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53</ci_lower_limit>
            <ci_upper_limit>7</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ApoB-48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68</ci_lower_limit>
            <ci_upper_limit>-28</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ApoB-48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3004</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50</ci_lower_limit>
            <ci_upper_limit>24</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ApoB-100</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6135</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10</ci_lower_limit>
            <ci_upper_limit>7</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ApoB-100</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1127</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ApoB-100</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2576</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ApoCIII</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0017</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52</ci_lower_limit>
            <ci_upper_limit>-16</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ApoCIII</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68</ci_lower_limit>
            <ci_upper_limit>-45</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ApoCIII</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61</ci_lower_limit>
            <ci_upper_limit>-29</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ApoAI</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0193</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20</ci_lower_limit>
            <ci_upper_limit>-2</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ApoAI</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33</ci_lower_limit>
            <ci_upper_limit>-19</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ApoAI</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0063</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23</ci_lower_limit>
            <ci_upper_limit>-4</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FFA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8873</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21</ci_lower_limit>
            <ci_upper_limit>23</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>FFA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4404</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB</param_type>
            <param_value>-8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27</ci_lower_limit>
            <ci_upper_limit>15</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>FFA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9665</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB]</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22</ci_lower_limit>
            <ci_upper_limit>27</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lp[a]</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4133</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB]</param_type>
            <param_value>-7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Lp[a]</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4750</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB]</param_type>
            <param_value>-6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20</ci_lower_limit>
            <ci_upper_limit>11</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Lp[a]</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6354</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference in % CFB]</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20</ci_lower_limit>
            <ci_upper_limit>15</ci_upper_limit>
            <estimate_desc>Mean difference in percent (%) change from baseline (CFB) based on difference in least square mean (LSM) of log (Primary Analysis Time Point/Baseline) was estimated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose at the Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose at the Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" lower_limit="-21.74" upper_limit="12.95"/>
                    <measurement group_id="O2" value="-21.6" lower_limit="-40.05" upper_limit="-3.17"/>
                    <measurement group_id="O3" value="9.4" lower_limit="-9.53" upper_limit="28.40"/>
                    <measurement group_id="O4" value="-2.2" lower_limit="-25.33" upper_limit="20.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1799</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-17.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.53</ci_lower_limit>
            <ci_upper_limit>8.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2867</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>13.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.83</ci_lower_limit>
            <ci_upper_limit>39.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8812</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.78</ci_lower_limit>
            <ci_upper_limit>31.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin A1c (HbA1c) at the Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1c (HbA1c) at the Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="-0.27" upper_limit="0.64"/>
                    <measurement group_id="O2" value="-0.09" lower_limit="-0.56" upper_limit="0.37"/>
                    <measurement group_id="O3" value="0.26" lower_limit="-0.22" upper_limit="0.75"/>
                    <measurement group_id="O4" value="0.35" lower_limit="-0.18" upper_limit="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3995</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8155</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6466</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Insulin at the Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Insulin at the Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>milli-international units per liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" lower_limit="-5.74" upper_limit="5.55"/>
                    <measurement group_id="O2" value="-1.48" lower_limit="-7.51" upper_limit="4.54"/>
                    <measurement group_id="O3" value="-0.23" lower_limit="-6.37" upper_limit="5.91"/>
                    <measurement group_id="O4" value="3.48" lower_limit="-3.94" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7393</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.66</ci_lower_limit>
            <ci_upper_limit>6.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9744</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.45</ci_lower_limit>
            <ci_upper_limit>8.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4477</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.75</ci_lower_limit>
            <ci_upper_limit>12.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in and HOMA-IR at the Primary Analysis Time Point</title>
        <description>HOMA-IR is a method used to quantify insulin resistance. HOMA-IR is expressed as the following: HOMA-IR = fasting serum insulin (μU/mL) * fasting plasma glucose (mmol/L)/22.5. A negative change from Baseline indicates improvement. An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 milligrams (mg) SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in and HOMA-IR at the Primary Analysis Time Point</title>
          <description>HOMA-IR is a method used to quantify insulin resistance. HOMA-IR is expressed as the following: HOMA-IR = fasting serum insulin (μU/mL) * fasting plasma glucose (mmol/L)/22.5. A negative change from Baseline indicates improvement. An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>index</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.119" lower_limit="-3.47" upper_limit="3.24"/>
                    <measurement group_id="O2" value="-1.914" lower_limit="-5.50" upper_limit="1.67"/>
                    <measurement group_id="O3" value="0.141" lower_limit="-3.52" upper_limit="3.80"/>
                    <measurement group_id="O4" value="2.013" lower_limit="-2.41" upper_limit="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4710</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.794</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.72</ci_lower_limit>
            <ci_upper_limit>3.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9169</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.260</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.68</ci_lower_limit>
            <ci_upper_limit>5.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4484</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.133</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.44</ci_lower_limit>
            <ci_upper_limit>7.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fructosamine at Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fructosamine at Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>μmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" lower_limit="-5.40" upper_limit="31.80"/>
                    <measurement group_id="O2" value="-10.0" lower_limit="-29.34" upper_limit="9.40"/>
                    <measurement group_id="O3" value="1.8" lower_limit="-17.92" upper_limit="21.44"/>
                    <measurement group_id="O4" value="15.1" lower_limit="-7.74" upper_limit="38.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0916</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-23.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.17</ci_lower_limit>
            <ci_upper_limit>3.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4032</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-11.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.51</ci_lower_limit>
            <ci_upper_limit>15.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8959</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.56</ci_lower_limit>
            <ci_upper_limit>31.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycated Albumin at the Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycated Albumin at the Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>grams per deciliter (g/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0033" lower_limit="-0.07" upper_limit="0.07"/>
                    <measurement group_id="O2" value="-0.0553" lower_limit="-0.13" upper_limit="0.02"/>
                    <measurement group_id="O3" value="-0.0133" lower_limit="-0.09" upper_limit="0.06"/>
                    <measurement group_id="O4" value="0.0280" lower_limit="-0.06" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3202</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.0520</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8485</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.0100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5812</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.0314</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weight at the Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight at the Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-2.19" upper_limit="0.18"/>
                    <measurement group_id="O2" value="-0.57" lower_limit="-1.76" upper_limit="0.62"/>
                    <measurement group_id="O3" value="-0.99" lower_limit="-2.15" upper_limit="0.17"/>
                    <measurement group_id="O4" value="-1.33" lower_limit="-2.57" upper_limit="-0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6157</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9869</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.66</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7084</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.07</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>millimeters of mercury (mmHg)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.66" lower_limit="-6.66" upper_limit="3.33"/>
                    <measurement group_id="O2" value="1.13" lower_limit="-4.07" upper_limit="6.34"/>
                    <measurement group_id="O3" value="0.42" lower_limit="-4.67" upper_limit="5.51"/>
                    <measurement group_id="O4" value="-3.29" lower_limit="-8.76" upper_limit="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.35" lower_limit="-5.71" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.75" lower_limit="-1.70" upper_limit="5.20"/>
                    <measurement group_id="O3" value="1.13" lower_limit="-2.26" upper_limit="4.52"/>
                    <measurement group_id="O4" value="-0.73" lower_limit="-4.35" upper_limit="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4431</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.41</ci_lower_limit>
            <ci_upper_limit>10.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>SBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5630</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.05</ci_lower_limit>
            <ci_upper_limit>9.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>SBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6634</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.06</ci_lower_limit>
            <ci_upper_limit>5.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0937</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>4.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>8.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>DBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1522</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.31</ci_lower_limit>
            <ci_upper_limit>8.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>DBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5188</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.35</ci_lower_limit>
            <ci_upper_limit>6.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Weight, SBP and DBP at Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the percent change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C6</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 milligrams (mg) SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Weight, SBP and DBP at Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the percent change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" lower_limit="-2.23" upper_limit="0.27"/>
                    <measurement group_id="O2" value="-0.40" lower_limit="-1.66" upper_limit="0.85"/>
                    <measurement group_id="O3" value="-1.10" lower_limit="-2.32" upper_limit="0.12"/>
                    <measurement group_id="O4" value="-1.38" lower_limit="-2.69" upper_limit="-0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" lower_limit="-4.57" upper_limit="3.46"/>
                    <measurement group_id="O2" value="1.80" lower_limit="-2.38" upper_limit="5.98"/>
                    <measurement group_id="O3" value="0.68" lower_limit="-3.41" upper_limit="4.77"/>
                    <measurement group_id="O4" value="-1.79" lower_limit="-6.17" upper_limit="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" lower_limit="-6.22" upper_limit="2.56"/>
                    <measurement group_id="O2" value="3.18" lower_limit="-1.33" upper_limit="7.69"/>
                    <measurement group_id="O3" value="2.11" lower_limit="-2.32" upper_limit="6.54"/>
                    <measurement group_id="O4" value="-0.13" lower_limit="-4.85" upper_limit="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Weight</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5299</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.24</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Weight</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8919</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.89</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Weight</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6653</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.25</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4213</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.43</ci_lower_limit>
            <ci_upper_limit>8.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>SBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6696</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.49</ci_lower_limit>
            <ci_upper_limit>6.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>SBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6819</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.20</ci_lower_limit>
            <ci_upper_limit>4.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1171</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>5.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>11.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>DBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2155</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.33</ci_lower_limit>
            <ci_upper_limit>10.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>DBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6034</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.79</ci_lower_limit>
            <ci_upper_limit>8.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hepatic Fat Fraction (HFF) by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at the Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hepatic Fat Fraction (HFF) by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at the Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>percentage (Hepatic Fat Fraction)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.69" lower_limit="-4.09" upper_limit="0.71"/>
                    <measurement group_id="O2" value="-0.71" lower_limit="-3.21" upper_limit="1.78"/>
                    <measurement group_id="O3" value="2.39" lower_limit="-0.16" upper_limit="4.94"/>
                    <measurement group_id="O4" value="-0.12" lower_limit="-2.87" upper_limit="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5752</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.48</ci_lower_limit>
            <ci_upper_limit>4.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0230</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>4.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>7.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3965</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.10</ci_lower_limit>
            <ci_upper_limit>5.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Hepatic Fat Fraction (HFF) by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at the Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the percent change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Hepatic Fat Fraction (HFF) by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at the Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the percent change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.09" lower_limit="-23.63" upper_limit="9.45"/>
                    <measurement group_id="O2" value="5.34" lower_limit="-11.83" upper_limit="22.52"/>
                    <measurement group_id="O3" value="18.94" lower_limit="1.38" upper_limit="36.51"/>
                    <measurement group_id="O4" value="5.18" lower_limit="-13.80" upper_limit="24.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3023</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>12.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.39</ci_lower_limit>
            <ci_upper_limit>36.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0350</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>26.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.87</ci_lower_limit>
            <ci_upper_limit>50.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3374</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>12.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.02</ci_lower_limit>
            <ci_upper_limit>37.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HFF ≤ 8% by MRI-PDFF at the Primary Analysis Time Point</title>
        <description>The percentage of participants who achieved HFF ≤ 8% at the Primary Analysis Time Point was compared between each ISIS 703802 treatment group and pooled placebo group using a logistic regression model.</description>
        <time_frame>Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 milligrams (mg) SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HFF ≤ 8% by MRI-PDFF at the Primary Analysis Time Point</title>
          <description>The percentage of participants who achieved HFF ≤ 8% at the Primary Analysis Time Point was compared between each ISIS 703802 treatment group and pooled placebo group using a logistic regression model.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="8.7"/>
                    <measurement group_id="O3" value="4.5"/>
                    <measurement group_id="O4" value="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fatty Liver Index (FLI) at the Primary Analysis Time Point</title>
        <description>The FLI was calculated by the following formula: FLI =(e0.953×loge[triglycerides]+0.139× Body Mass Index [BMI]+0.718×loge Gamma- Glutamyl Transferase [GGT]+0.053×waistcircumference-15.745)/ (1 + e0.953×loge[triglycerides]+0.139×BMI+0.718×loge [GGT]+0.053×waistcircumference-15.745) × 100. An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fatty Liver Index (FLI) at the Primary Analysis Time Point</title>
          <description>The FLI was calculated by the following formula: FLI =(e0.953×loge[triglycerides]+0.139× Body Mass Index [BMI]+0.718×loge Gamma- Glutamyl Transferase [GGT]+0.053×waistcircumference-15.745)/ (1 + e0.953×loge[triglycerides]+0.139×BMI+0.718×loge [GGT]+0.053×waistcircumference-15.745) × 100. An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>index</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.50" lower_limit="-8.21" upper_limit="1.22"/>
                    <measurement group_id="O2" value="-6.08" lower_limit="-11.08" upper_limit="-1.09"/>
                    <measurement group_id="O3" value="-9.21" lower_limit="-13.99" upper_limit="-4.44"/>
                    <measurement group_id="O4" value="-8.07" lower_limit="-13.06" upper_limit="-3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4583</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.49</ci_lower_limit>
            <ci_upper_limit>4.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0943</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-5.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.43</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1909</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-4.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.45</ci_lower_limit>
            <ci_upper_limit>2.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) at the Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 milligrams (mg) SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) at the Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>units per liter (U/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" lower_limit="-8.48" upper_limit="3.99"/>
                    <measurement group_id="O2" value="4.8" lower_limit="-1.75" upper_limit="11.38"/>
                    <measurement group_id="O3" value="12.5" lower_limit="6.30" upper_limit="18.79"/>
                    <measurement group_id="O4" value="6.6" lower_limit="-0.06" upper_limit="13.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" lower_limit="-5.50" upper_limit="1.93"/>
                    <measurement group_id="O2" value="3.2" lower_limit="-0.71" upper_limit="7.12"/>
                    <measurement group_id="O3" value="6.7" lower_limit="2.93" upper_limit="10.37"/>
                    <measurement group_id="O4" value="4.7" lower_limit="0.77" upper_limit="8.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ALT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1294</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>7.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.10</ci_lower_limit>
            <ci_upper_limit>16.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ALT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>14.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.98</ci_lower_limit>
            <ci_upper_limit>23.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ALT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0594</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>8.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>18.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AST</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0730</p_value>
            <method>ANCOVA</method>
            <param_type>[Least Squares Mean Difference</param_type>
            <param_value>5.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>10.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>AST</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0020</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>8.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.17</ci_lower_limit>
            <ci_upper_limit>13.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>AST</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0200</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>12.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Leptin at the Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Leptin at the Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>μg/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="-1.37" upper_limit="3.27"/>
                    <measurement group_id="O2" value="-0.24" lower_limit="-2.66" upper_limit="2.18"/>
                    <measurement group_id="O3" value="-0.57" lower_limit="-2.99" upper_limit="1.85"/>
                    <measurement group_id="O4" value="-3.23" lower_limit="-5.90" upper_limit="-0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4812</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.55</ci_lower_limit>
            <ci_upper_limit>2.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3679</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.88</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0210</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-4.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.72</ci_lower_limit>
            <ci_upper_limit>-0.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Adiponectin at the Primary Analysis Time Point</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Adiponectin at the Primary Analysis Time Point</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>milligrams per liter (mg/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="-0.20" upper_limit="0.60"/>
                    <measurement group_id="O2" value="0.05" lower_limit="-0.37" upper_limit="0.48"/>
                    <measurement group_id="O3" value="-0.18" lower_limit="-0.61" upper_limit="0.24"/>
                    <measurement group_id="O4" value="-0.18" lower_limit="-0.65" upper_limit="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6227</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1950</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.97</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2271</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Subcutaneous Adipose Tissue (SAT) and Visceral Adipose Tissue (VAT) by Single Slice MRI at the Primary Analysis Timepoint</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Subcutaneous Adipose Tissue (SAT) and Visceral Adipose Tissue (VAT) by Single Slice MRI at the Primary Analysis Timepoint</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>mm^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.61" lower_limit="-156.99" upper_limit="105.76"/>
                    <measurement group_id="O2" value="-8.55" lower_limit="-145.57" upper_limit="128.47"/>
                    <measurement group_id="O3" value="7.31" lower_limit="-139.08" upper_limit="153.70"/>
                    <measurement group_id="O4" value="-41.91" lower_limit="-192.12" upper_limit="108.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.83" lower_limit="-112.13" upper_limit="141.79"/>
                    <measurement group_id="O2" value="19.78" lower_limit="-109.07" upper_limit="148.63"/>
                    <measurement group_id="O3" value="-9.42" lower_limit="-149.27" upper_limit="130.42"/>
                    <measurement group_id="O4" value="36.85" lower_limit="-105.21" upper_limit="178.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SAT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8591</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>17.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-173.57</ci_lower_limit>
            <ci_upper_limit>207.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>SAT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7404</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>32.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-164.11</ci_lower_limit>
            <ci_upper_limit>229.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>SAT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8711</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-16.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-215.50</ci_lower_limit>
            <ci_upper_limit>182.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>VAT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9569</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>4.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-176.64</ci_lower_limit>
            <ci_upper_limit>186.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>VAT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8025</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-24.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-216.53</ci_lower_limit>
            <ci_upper_limit>168.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>VAT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8202</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>22.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-170.09</ci_lower_limit>
            <ci_upper_limit>214.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist Circumference by Single Slice MRI at the Primary Analysis Timepoint</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg Q4W</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Waist Circumference by Single Slice MRI at the Primary Analysis Timepoint</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>cm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" lower_limit="-6.85" upper_limit="2.35"/>
                    <measurement group_id="O2" value="-2.14" lower_limit="-6.77" upper_limit="2.49"/>
                    <measurement group_id="O3" value="-2.95" lower_limit="-7.51" upper_limit="1.61"/>
                    <measurement group_id="O4" value="-0.59" lower_limit="-5.41" upper_limit="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9734</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.47</ci_lower_limit>
            <ci_upper_limit>6.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8333</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.25</ci_lower_limit>
            <ci_upper_limit>5.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6207</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.99</ci_lower_limit>
            <ci_upper_limit>8.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist to Hip Ratio (WHR) at the Primary Analysis Timepoint</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Waist to Hip Ratio (WHR) at the Primary Analysis Timepoint</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-0.03" upper_limit="0.04"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.02" upper_limit="0.05"/>
                    <measurement group_id="O3" value="-0.01" lower_limit="-0.04" upper_limit="0.02"/>
                    <measurement group_id="O4" value="0.01" lower_limit="-0.03" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8026</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4917</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8916</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Mass Index (BMI) at the Primary Analysis Timepoint</title>
        <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
        <time_frame>Baseline, Week 27 for Cohort A, and Week 25 for Cohorts B and C</time_frame>
        <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg QW</title>
            <description>Participants received ISIS 703802, 20 mg SC once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Mass Index (BMI) at the Primary Analysis Timepoint</title>
          <description>An ANCOVA model was performed on the change from Baseline to Primary Analysis Time Point.</description>
          <population>FAS population included all participants who were randomized and received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure</population>
          <units>kg/m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" lower_limit="-0.69" upper_limit="0.15"/>
                    <measurement group_id="O2" value="-0.17" lower_limit="-0.59" upper_limit="0.26"/>
                    <measurement group_id="O3" value="-0.37" lower_limit="-0.79" upper_limit="0.04"/>
                    <measurement group_id="O4" value="-0.50" lower_limit="-0.94" upper_limit="-0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7280</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7354</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4682</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
        <description>An AE was defined as any unfavorable and unintended sign (including a clinically-significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE was considered related to the investigational drug product. TEAEs were defined as adverse events that occurred after the first administration of study drug.</description>
        <time_frame>Up to 13 weeks post treatment period (up to 39 weeks)</time_frame>
        <population>Safety set included all participants who were randomized and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
            <description>Participants received ISIS 703802, 40 milligrams (mg) SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
            <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: ISIS 703802, 20 mg Q4W</title>
            <description>Participants received ISIS 703802, 20 mg once every week for 26 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
          <description>An AE was defined as any unfavorable and unintended sign (including a clinically-significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE was considered related to the investigational drug product. TEAEs were defined as adverse events that occurred after the first administration of study drug.</description>
          <population>Safety set included all participants who were randomized and received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 13 weeks post-treatment period (up to 39 weeks)</time_frame>
      <desc>Safety population included all participants who were randomized and received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pooled Placebo</title>
          <description>Participants from each cohort received placebo at a dose-matched volume of study drug, SC.</description>
        </group>
        <group group_id="E2">
          <title>Cohort B: ISIS 703802, 40 mg Q4W</title>
          <description>Participants received ISIS 703802, 40 milligrams (mg) SC once every 4 weeks for 6 doses.</description>
        </group>
        <group group_id="E3">
          <title>Cohort C: ISIS 703802, 80 mg Q4W</title>
          <description>Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.</description>
        </group>
        <group group_id="E4">
          <title>Cohort A: ISIS 703802, 20 mg QW</title>
          <description>Participants received ISIS 703802, 20 mg once every week for 26 doses.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Actinomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Akcea Therapeutics</organization>
      <phone>617-207-0289</phone>
      <email>clinicalstudies@akceatx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

